Get the latest news, insights, and market updates on IBRX (ImmunityBio, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Insiders Favor These 3 Leading Growth Companies
As February begins, U.S. stock markets are showing strong momentum, with major indexes like the Dow Jones Industrial Average and S&P 500 posting significant gains. In this environment of market optimism, investors often look for growth companies with high insider ownership as an indicator of confidence and potential resilience amidst economic shifts. Feb 19, 2026 - $IBRX
ImmunityBio (IBRX) Soars to New High on Anktiva Future Expansion
We recently published 10 Market Winners With Stunning Gains. Immunitybio Inc. (NASDAQ:IBRX) was one of the best performers on Wednesday. ImmunityBio soared to a new 52-week high on Wednesday, as investors gobbled up shares over an aggressive international expansion for its therapy, Anktiva. At intra-day trading, the stock climbed to its highest price of $8.68 […] Feb 19, 2026 - $IBRX
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. Feb 19, 2026 - $IBRX
ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it has initiated a Phase 2 clinical trial evaluating a novel combination immunotherapy for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). Meanwhile, on January 26, ImmunityBio Inc. (NASDAQ:IBRX) amended a […] Feb 19, 2026 - $IBRX
ImmunityBio (IBRX) Is Up 29.0% After EU Clears First ANKTIVA+BCG Immunotherapy For NMIBC CIS
In February 2026, ImmunityBio announced that the European Commission granted conditional marketing authorization for ANKTIVA in combination with BCG to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors, across 33 countries. This decision makes ANKTIVA plus BCG the first immunotherapy option authorized in Europe for these high-risk patients, whose main alternative had been radical cystectomy, and is underpinned by... Feb 19, 2026 - $IBRX
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
CULVER CITY, Calif., February 19, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for eligible patients in the European Union with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), with or without papillary disease. ImmunityBio also announced the establishment of an I Feb 19, 2026 - $IBRX
ImmunityBio’s EU Anktiva Nod Sparks Questions On Valuation And Momentum
ImmunityBio (NasdaqGS:IBRX) has received conditional marketing authorization from the European Commission for Anktiva in combination with BCG. The approval covers treatment of BCG unresponsive non muscle invasive bladder cancer across 33 EU and associated countries. Anktiva becomes the first immunotherapy option in Europe for this form of bladder cancer, addressing a major unmet medical need. For ImmunityBio, this decision comes as the stock trades around $8.54, with moves of 29.0% over the... Feb 19, 2026 - $IBRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple